Abstract
Introduction
Population-based disease management programs aim to provide effective care to all persons with a given disease across all clinical settings (Elwood 1998; Epstein and Sherwood 1996) . Key program elements include use of evidence-based clinical guidelines and systematic reporting of care processes and outcomes (Epstein and Sherwood 1996; Ellrodt et al 1997) . Chronic diseases such as asthma (Homer 1997) , diabetes (McCullough et al 1994) , and congestive cardiac failure (Rich et al 1995) have attracted widest attention to date.
In this article we describe our initial experience with a coronary artery disease (CAD) management program in the West Moreton Health District of Queensland -the West Moreton Coronary Outcomes Program (WESTCOP). The District serves a region of 180000 residents centred on the city of Ipswich, 30km south-west of Brisbane. Medical care is provided by 4 resident physicians in internal medicine, 150 general practitioners (GPs), and two community hospitals -a 300 bed public hospital and a 100 bed private hospital.
Forming a stakeholder collaboration aimed at improving health outcomes
The mounting of effective disease management programs requires the involvement of local clinical opinion leaders in formulating and implementing clinical guidelines, evaluating practice, and feeding back results in ways that encourage practice improvement (Soumerai et al 1998) ; epidemiologists and data managers with expertise in collecting and analysing data (Simpson & Gordon 1998) ; and health care managers and consumer advocates to ensure program planning and implementation are aligned with managerial imperatives and community opinion (Backer 1995) .
In late 1995 a steering committee was formed comprising representatives from the community hospitals, the West Moreton Public Health Unit, and the Ipswich and West Moreton Division of General Practice. Program goals were agreed (see Table 2 ) and a Council convened (members listed in the appendix) to which three working groups reported: 1) a primary prevention group for co-ordinating population level prevention strategies; 2) a secondary and tertiary prevention group for overseeing community-based coronary rehabilitation and aftercare; and 3) an acute care group focussing on hospital management of acute coronary syndromes. (Krumholz et al 1997) Adjunctive treatments β-blockers Aspirin 170 21% (Soumerai et al 1997) ACEIs 125 76% (Krumholz et al 1996) LLAs 10-80+ 45% (Krumholz et al 1997) 33** 26% (Khong 1998) Cardiac rehabilitation 32 58% (Melville et al 1999) Coronary revascularisation 2++ 74% (Leape et al 1999) *Number needed to treat to save one life (Source: Yusuf et al 1998) + Patients with left ventricular dysfunction ** Patients whose serum cholesterol level was equal to or greater than 5.5 mmol/l ++ Patients with left main disease or triple vessel disease with left ventricular dysfunction (Grimshaw & Russell 1993) ; and they contain care recommendations which, according to the strength of associated evidence, can be translated into criteria for evaluating the quality of care provided (Baker & Fraser 1995) .
Separate guidelines for the hospital and post-hospital management of AMI and unstable angina were developed and issued using recommended methods (NHMRC 1995) . A guideline working group that included local lead clinicians and a senior cardiologist made adaptations to guidelines from the American College of Cardiology and American Heart Association (Ryan et al 1996) .
Guideline recommendations were assessed by an end-user group to ensure applicability, flexibility and attainability given local clinical culture and resource constraints. Guideline format was also evaluated with respects to perceived clarity, brevity and utility in busy clinical settings. Following various revisions, the guidelines were distributed in August 1996 as booklets to all clinicians in the West Moreton region, were reinforced in workshops conducted by clinical opinion leaders, and publicised in the launching of a community-based cardiac rehabilitation service. As a result of end-user surveys, guidelines were updated, reformatted and re-issued with further workshops in mid-1999. At this time, all hospital clinicians were aware of and had used the guidelines at least once, as had 47% (70) of all GPs.
Defining performance measures for evaluating care
Optimal disease management requires systematic and prospective collection and feedback of data on processes and outcomes of care (Mugford et al 1991) . In recent years, the measurement and reporting of clinical indicators has been promoted by medical colleges and other groups (ACHS 1996; National Hospitals Outcomes Program, 1997) . Whilst indicators for hospital care have existed for some years, indicators for general practice and community health are only now being promoted (McColl et al 1998) .
Developing quality indicators. Guideline recommendations relating to evidence-based processes of care (Table 3) formed the basis for sets of clinical indicators -statistics which reflect, directly or indirectly, the performance of the healthcare system in providing optimal care for target populations (National Hospitals Outcomes Program, 1997). We developed indicators for AMI which we considered fulfilled the following criteria:
• reliability given that medical records and self-report questionnaires were to be used as source documents (Lambert-Huber et al 1994);
• sensitivity for detecting care considered suboptimal in light of guideline recommendations (Mant & Hicks 1995) ;
• validity, relevance and interpretability in the eyes of practising clinicians (Hofer et al 1997) ;
• feasibility in terms of the opportunity costs to patient, clinician and program staff of collecting necessary data;
• robustness in that data within source documents were relatively immune to distortion or gaming effects; and
• responsiveness to changes in practice as a result of feedback and education. 
β-blockers
Inclusion criteria: all AMI patients+ 70% 60%
Exclusion criteria: cardiogenic shock, past or current heart failure, asthma or chronic obstructive lung disease, bradyarrhythmia requiring pacing
Aspirin
Inclusion criteria: all AMI patients+ 94% 85%
Exclusion criteria: active gastrointestinal bleeding in hospital or concurrent warfarin therapy
Angiotensin-converting enzyme inhibitors (ACEIs)
Inclusion criteria: all AMI patients+ who have past history or current clinical features of heart failure OR 63% 55%
have echo evidence of moderate to severe left ventricular dysfunction OR have had an anterior infarction Exclusion criteria: nil
Lipid-lowering agents (LLAs)
Inclusion criteria: all AMI patients+ whose random total serum cholesterol level on admission was 64% 55%
mmol/l or greater
Exclusion criteria: nil
Enrolment into post-discharge Cardiac rehabilitation (CR)
Inclusion criteria: all AMI patients+ N/A 70% Exclusion criteria: very old age (<85 years), marked physical frailty, terminal illness, uncontrolled heart failure or unstable angina -not measured but estimated from trials to comprise approximately 70% of patients
Stress ECG testing
Inclusion criteria: all AMI patients+ N/A 70% Exclusion criteria: advanced age, locomotor incapacity, uninterpretable ECG -not measured but estimated from trials to comprise approximately 30% of patients
Coronary angiography
Inclusion criteria: all AMI patients+ who had re-infarction, post-infarct angina or strongly positive exercise N/A 40% ECG test -not measured but estimated from cohort studies to comprise up to 40% of patients Exclusion criteria: nil * A=number of pre-intervention AMI patients who met process eligibility criteria ('indicative' threshold) with exception of CR, stress ECG testing and CA for which criteria were not measured; B= quality threshold for process indicators (with exception of lysis) calculated from 'indicative' threshold by subtracting 10% and rounding off to nearest 5%. + Patients discharged alive and not transferred to tertiary centre Tables 3 and 4 , and are expressed as the rate, proportion or mean applicable to the measure.
Process measures related to: 1) use of thrombolysis, and time between admission and administration ('door-to-needle' time); 2) prescribing rates at discharge of adjunctive drugs: β-blockers, aspirin, angiotensin-converting enzyme inhibitors (ACEIs), and lipid-lowering agents (LLAs); and 3) utilisation of cardiac rehabilitation (CR), stress ECG testing and coronary angiography (CA). Patient eligibility criteria for specific interventions are detailed in Table 3 . Outcome measures (see Table 4 ) comprised in-hospital mortality rate, complication rates and length of stay. Post-hospital (Maintenance) Care. Process measures for posthospital care comprised frequency of: 1) assessment of coronary risk factors; 2) provision of advice about smoking cessation, diet, exercise and lifestyle changes, and 3) ongoing prescription of adjuvant drugs. Outcome measures measured at 3 and 18 months post-discharge comprised: 1) proportions of patients achieving ideal levels of serum cholesterol, blood pressure and body weight; 2) readmission rates for cardiac events and procedures; 3) return to work; 4) quality of life scores (as measured by a validated disease-specific questionnaire [Valenti et al 1996] ); and 5) all-cause and CAD-specific mortality. 
Process and Outcome Measures for

Deriving and validating quality indicator thresholds
In evaluating practice, clinicians ask: 'Improve care in relation to what?' which leads to: 'What are realistic benchmarks/targets/'best practice' standards?' Quality of care was evaluated using explicit process and outcome indicators (see Table 3 ) for which evidence-based quality thresholds (or targets) were derived as explained below. This evaluation method was considered superior to implicit peer review (Hayward et al 1993) or comparative profiling of local practice patterns devoid of any external benchmarking (Balas et al 1995) .
For purposes of provider feedback, process and outcome indicators (with the exception of thrombolysis) were respectively reported as the proportion of all patients in each consecutive 6 month cohort who received the intervention or demonstrated the particular outcome. Quality thresholds were linked to each of these indicators such that providers could accurately quantify threshold-practice gaps, and target efforts towards narrowing these gaps.
Quality thresholds for process indicators were derived in a 2-step procedure as follows: an 'indicative' threshold was calculated as the proportion of the first 133 AMI patients entered into the registry during a 6 month baseline period (derivation cohort) who met pre-specified eligibility criteria for each intervention based on a review of the literature published up to early 1996. Such patients should, by definition, receive that intervention. This indicative threshold was then adjusted downwards by 10% and rounded off to the nearest 5% to give a 'quality' threshold which represented an attainable standard of care that allowed for variation in patient characteristics that might occur between consecutive cohorts. On the basis of previously cited studies, it was hypothesised a priori (and confirmed subsequently) that under-utilisation rather than over-utilisation of effective interventions was the quality issue to be addressed.
Quality thresholds for outcome indicators were those observed in 'best practice' sites as reported in the literature, provided they were considered applicable to our program by virtue of similarities in patient demographics and community hospital setting. Separate sets of indicators were developed for hospital and post-hospital care.
Process indicators for hospital care
Thrombolysis: As thrombolysis has a low benefit-risk ratio (FTT Collaborative Group 1994), patient eligibility for thrombolysis was determined precisely using the criteria listed in Table 3 . 'Door-to-needle' time was measured and deemed to be ideal if less than 1 hour (Boersma et al 1996) .
β-blockers: On the basis of multiple trials (The Beta-Blocker Pooling Project Research Group 1988) and practice norms, 64% of the derivation cohort were considered eligible for β-blocker therapy.
Aspirin: Meta-analyses of anti-platelet trials (Anti-platelet Trialists' Collaboration 1994) suggested at least 90% of patients were eligible to receive aspirin.
Angiotensin-converting enzyme inhibitors (ACEIs):
In different trials (Garg et al 1995; Lantini et al 1995) , ACEIs were prescribed for all AMI patients, or only those 60% of patients with clinical and/or echocardiographic evidence of left ventricular (LV) dysfunction (Silver et al 1994) in whom mortality reduction was greatest. We decided that patient eligibility should depend on the extent of LV dysfunction as detailed in Table 3 .
Lipid-lowering agents: Treatment with statin drugs was indicated in patients whose serum cholesterol level was above 5.5 mmol/l (Scandinavian Simvistatin Survival Study Group 1994). Population-based cholesterol profiles (National Centre for Health Statistics 1996) defined 50% of the derivation cohort as being eligible.
Cardiac rehabilitation: Results of a meta-analysis suggested 70% of AMI patients were eligible to participate in formal cardiac rehabilitation (CR) programs (Oldridge et al 1988) . Given the multiple, often unrecorded patient variables which influence the decision to refer, patient eligibility was not measured in the derivation cohort. Instead the published figure of 70% was accepted as a surrogate measure of best practice.
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Risk stratification procedures: For reasons similar to those stated above, the quality threshold for stress testing following AMI was taken to be 70% as observed in a large international trial population of lysis-eligible patients (Villello et al 1995) . The threshold for post-AMI coronary angiography (CA) was, on the basis of an expert position paper (Peterson et al 1997) taken to be 40%, comprising those patients with spontaneous or provocable ischaemia who were considered to warrant this procedure.
Outcome indicators for hospital care
Quality thresholds for outcome indicators were obtained from a US AMI registry surveying multiple acute care hospitals involved in a regional quality improvement project (Maynard et al 1993; Every et al 1996) . Thresholds consisted of an in-hospital mortality rate of 10%, reinfarction rate of 4%, and mean length of hospital stay (LOS) of 6 days.
Post-hospital care indicators
The quality thresholds for post-hospital process of care indicators were as follows: at least 85% of patients attending their GPs during the previous 3 months should have had risk factors assessed (smoking status, blood pressure, cholesterol level, body mass index), and appropriate advice given. Thresholds for prescription of adjuvant drugs were identical to those for hospital care as these therapies, once initiated, were intended to be administered indefinitely in virtually all patients. Thresholds for outcome indicators were not formulated given the paucity of literature concerning optimal indices of readmission, quality of life and mortality relevant to ambulatory care.
Implementing standardised data collection systems
Patient eligibility: A registry was set up for the prospective collection of data on hospital and posthospital care of all patients who met the following criteria: 1) patients were residents of West Moreton; 2) AMI was the principal diagnosis at discharge; and 3) the diagnosis of AMI was confirmed using accepted diagnostic criteria.
Patient enrolment:
Patients could be entered into the registry at three points: in hospital (the majority); at the time of commencement of CR; or when consulting a general practitioner. Informed consent to receive questionnaires and allow program staff to access medical records was obtained from participating patients. Program methods were approved by the West Moreton Clinical Research Ethics Committee.
Hospital Data Collection:
Cardiology-trained nurses abstracted in-hospital data on baseline patient characteristics, clinical presentation, tests, treatments, complications, discharge medications and risk stratification procedures. Baseline quality of life questionnaires were also administered.
Post-hospital Data Collection:
Patient progress at 3 and 18 months post-discharge was monitored by mail-out to all consenting patients of three instruments: repeat quality of life questionnaire and a personal profile -both for patient self-completion -and a clinical patient profile to be completed by the GP during a scheduled visit.
Central database: Data on hospital care contained within hospital databases were merged with post-hospital data contained within the GP Division database to create a central database located within the Public Health Unit for purposes of collation and analysis.
Feeding back indicator results to key stakeholders
Approximately every 6 months, comparative analyses of hospital care indicators were circulated to consultant physicians, hospital medical registrars, senior staff in emergency departments, and senior medical executives in all hospitals and the Division of GP. Indicators for the current period were compared with those of previous periods and with quality thresholds. Because of resource limitations and initial targeting of efforts to evaluating hospital care, feedback of post-hospital care indicators has only recently commenced.
Methodological issues
There were several issues regarding clinical indicators and quality thresholds. Reporting the proportion of all patients who received an intervention as a feedback indicator may be criticised as being too crude a measure of the extent to which specific interventions are provided to patients most likely to benefit. This format was chosen for several reasons: it simplified the process of analysis and reporting; it was readily understood by providers; and it was identical to that reported in similar evaluative studies performed elsewhere against which local figures could be compared. Such 'population-level' process indicators have both advantages and disadvantages compared to 'patient-level' indicators which are based on specific eligibility criteria (see table 5 ). However, the use of specific patient eligibility criteria to develop patient-level process quality thresholds also invites several criticisms. First, intervention-specific exclusion criteria may omit certain contra-indications and thus, by inflating the denominator of eligible patients, lead to calculated utilisation rates suggesting sub-optimal care. This concern was addressed in the Co-operative Cardiovascular Project (CCP) which evaluated the effects over 4 years of feedback on the use of reperfusion therapies, β-blockers, aspirin and smoking cessation programs in more than 250,000 AMI patients (Marciniak et al 1998) . This project calculated two rates for each process indicator: one defining all AMI patients as being eligible (a population-level indicator); and another defining a subset of 'ideal' patients who demonstrated none of up to 22 pre-specified exclusion criteria (a patient-level indicator). The magnitudes of improvements in both indicator rates were similar, suggesting that either method is effective in detecting suboptimal care. Second, indicators based on overly stringent eligibility criteria may have the reverse effect of persuading clinicians to deny certain patients potentially beneficial treatment. A sub-study of the CCP found that post-infarct use of β-blockers in patients with conditions often considered contra-indications (such as heart failure, lung disease and older age) achieved similar or higher absolute reductions in mortality compared to similarly treated patients with no such risk factors (Gottlieb et al 1998) . Newly published research results support more liberal use of thrombolysis (Jha et al 1996) and lipid-lowering agents (Lewis et al 1998) in elderly patients, of β-blockers in patients with overt heart failure (Cleland et al 1999) , and of LLAs in patients with 'average' (4mmol/l or higher) serum cholesterol levels (The LIPID Study Group 1998).
Third, quality thresholds may assume that the statistically averaged benefit reported for trial populations is conferred equally on all patients deemed to be eligible. In real practice, patient subgroups exist for whom clinicians regard absolute benefits as being clinically negligible or outweighed by potential for harm (Oxman & Guyatt 1992) . This was the rationale behind the selective definition of eligibility for the use of ACEIs.
Finally, our quality thresholds can only be regarded, at best, as approximate or semi-validated benchmarks. However, we reasoned that such explicit, achievable thresholds, based on readily measurable and widely accepted eligibility criteria, needed to be stated if actionable feedback is to be provided to clinicians.
Data quality must be ensured if results are to be accurate and clinically credible. Initial audits revealed breaches of entry criteria and inaccuracies as to time of symptom onset and ECG interpretation of type (Q-wave versus non-Q-wave) and site of infarct. More stringent vetting of cases by physicians and simplification of ECG coding resulted in acceptable (κ>0.8) abstractorreviewer agreement. Hospital data entry is currently complete and associated with less than 3% error rate.
Benefits to Date
Patient profiling:The recording of patient characteristics and clinical course has allowed profiling of remediable risk factors and disease burden in this unselected AMI population. Such information informs efforts aimed at primary and secondary prevention, and deciding care for high-risk patients.
Benchmarking clinical practice: Reduced delays in administration of lysis, improved prescribing of lipid-lowering agents and lowering of in-hospital mortality and length of stay (p<0.05 for all results) were observed over a 2 year period as a result of indicator feedback and resultant practice reforms (Scott et al 1999) . Regarding post-hospital care, analyses revealed a progressive rise in the proportion of patients enrolled in CR programs (from 23 to 45%; p=0.001), a substantial fraction (at least 80%) undertaking regular exercise and adhering to diet, and no lowering of compliance rates for adjunctive treatments and smoking cessation (unpublished data).
Planning and resourcing of services:
The district health service and the public health unit have begun lobbying the state health department for additional funding for cardiac rehabilitation services to meet the estimated demand of 240 places per year compared to the current 96 funded places.
Exploring patient behaviour: Many AMI patients were observed to delay seeking medical assistance and present by private transport, both of which increased the risk of pre-hospital sudden death. The Division of General Practice has initiated efforts to educate at-risk patients in recognising and responding to AMI symptoms. The regional ambulance service is studying the reasons why a third of patients do not access this service following symptom onset.
Improving accuracy of discharge coding and admission diagnosis: In 19.4% of hospital records, AMI was not confirmed despite this being the coded discharge diagnosis. In addition, in 21.5% of cases of confirmed AMI, this diagnosis was not made on admission. These observations prompted development of an AMI verification algorithm for coding purposes, and more intense education of emergency staff in how to accurately and rapidly diagnose AMI. 
Challenges Confronted
No dedicated funding was obtainable during the first 3 years from institutional or Divisional operating budgets, or from state and federal agencies involved in outcomes and quality of care research. Whilst a pharmaceutical sponsor subsidised the costs of educational materials and cardiac rehabilitation services, the potential for conflicts of interest to arise between project program goals and commercial interests precluded any contractual arrangements (Harris 1996) .
Funding was instead obtained from the Health Information Centre of Queensland Health ($50,000 pa), the West Moreton Health District ($8000 pa) and the West Moreton Public Health Unit ($20,000 pa). This funding paid for 1.8 FTE program staff, although short-term contracts conditional on annual reapplication for funding resulted in high staff turnover with consequent losses in efficiency.
The proportion of patients consenting to receiving post-discharge questionnaires was initially only 40% but is currently more than 80%. At 3 months the response rate amongst consenters was 63% but dropped to less than 20% at 18 months. Simplified information and consent forms, reminder letters, personalised cards, and patient recruitment undertaken by attendant clinicians are all currently increasing recruitment and response rates. Of interest, there were no significant differences in patient characteristics between consenters and non-consenters, or between responders and non-responders (unpublished data).
Reconciling the needs of patient privacy and confidentiality with the ability to access and link patient data for purposes of outcomes research is proving problematic (Gostin & Hadley 1998) . Identified data relating to cause of death could only be obtained from death registries for consenting patients. Some reluctance to assist in program activities was encountered from a minority of GPs who viewed the program as irrelevant to the quality improvement needs of their individual practices. Such concerns have been countered by focus group discussions wherein program results and strategies have been discussed, and circulation of newsletters which feedback data about AMI care relevant to the needs of GPs.
Conclusion
The key components of this community-based disease management projectprogram accord with those of successful disease management programs (Todd & Nash 1997; Meechan et al 1995) , health outcome projects (Rissel et al 1998) and disease registries (Gray & Hampton 1993) described elsewhere. Longitudinal data on more than 700 AMI patients with follow-up extending to 6 months or more are currently being analysed. The program steps we have described are strongly recommended to others considering similar initiatives.
Ongoing priorities for WESTCOP include securing a more guaranteed long-term budget, developing better data collection methods, advancing research on derivation and validation of quality indicators, evaluating post-hospital care, and extending the current work to the care of patients with unstable angina. Such efforts will hopefully further optimise health care of patients with acute coronary syndromes in the West Moreton district. 
Appendix: Membership of the WESTCOP Council
